Importance of TMB Testing
- Identifying candidates for checkpoint inhibitors
- Predicting the likelihood of immunotherapy success
- Providing insights into tumor evolutionary dynamics
Book TMB Assessment in Saudi Arabia | Lahalak Medical Platform
Tumor Mutational Burden (TMB) is a critical biomarker that quantifies somatic mutations to predict clinical response to immunotherapy, enabling personalized cancer treatment strategies for improved patient outcomes and survival rates.
Scientific name: Tumor Mutational Burden (TMB) Assessment
An advanced genomic test that quantifies somatic mutations within a tumor's DNA. It helps clinicians identify patients likely to benefit from immunotherapy across various cancer types, optimizing personalized oncology care.
Service type
Advanced Genetic Test
Duration
15-30 minutes
Fasting
Fasting is not required
Included Services
- Sample collection (Blood or Tissue)
- Genomic sequencing analysis
- Detailed medical report
Medical Service Information
When is this test ordered?
- In cases of advanced or metastatic solid tumors
- When exploring treatment options beyond standard chemotherapy
- To guide personalized precision medicine strategies
Understanding Your Results
- High TMB: Often correlates with better clinical response to immunotherapy
- Low TMB: May suggest immunotherapy is less likely to be effective
- Results guide the selection of targeted oncology therapies
Conditions & Notices
- Requires a prior histopathology report
- Oncologist consultation is recommended before testing
Medical services you might also like
